Advisory Services Network’s UroGen Pharma URGN Stock Holding History

Advisory Services Network’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-553	Closed	-$9.94K	–	4491
2026 Q1	$9.94K	Buy	+553	New	+$11.1K	﹤0.01%	3563
2025 Q4	–	Sell	-550	Closed	-$11K	–	4124
2025 Q3	$11K	Buy	+550	New	+$9.88K	﹤0.01%	3246

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Advisory Services Network's URGN Position: Q2 2026 in Review

Advisory Services Network sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 553 shares — an estimated $9.94K sold.

Advisory Services Network first reported a position in URGN in Q3 2025 and held it in 2 quarters. The position peaked at $11K in Q3 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Advisory Services Network reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 553 UroGen Pharma shares in Q2 2026, an estimated $9.94K.
Advisory Services Network first reported a position in UroGen Pharma in Q3 2025 and held it in 2 quarters.
Advisory Services Network's UroGen Pharma position peaked at $11K in Q3 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.